Ana Marija Franceschi

Ana Marija Franceschi

Auto-generated profile, based on publicly available information

Ana Marija Franceschi

Department of Radiology, Neuroradiology Division, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SPSohil H. Patel
Sohil H. Patel
LPLaila M. Poisson
Laila M. Poisson
DBDaniel J. Brat
Daniel J. Brat
YZYueren Zhou
Yueren Zhou
LCLee Cooper
Lee Cooper
RJRajan Jain
Rajan Jain
Purpose: Lower-grade gliomas (WHO grade II/III) have been classified into clinically relevant molecular subtypes based on IDH and 1p/19q mutation status. The purpose was to investigate whether T2/FLAIR MRI features could distinguish between lower-grade glioma molecular subtypes. Experimental Design: MRI scans from the TCGA/TCIA lower grade glioma database (n = 125) were evaluated by two independent neuroradiologists to assess (i) presence/absence of homogenous signal on T2WI; (ii) presence/absence of “T2–FLAIR mismatch” sign; (iii) sharp or indistinct lesion margins; and (iv) presence/absence of peritumoral edema. Metrics with moderate–substantial agreement underwent consensus review and were correlated with glioma molecular subtypes. Somatic mutation, DNA copy number, DNA methylation, gene expression, and protein array data from the TCGA lower-grade glioma database were analyzed for molecular–radiographic associations. A separate institutional cohort (n = 82) was analyzed to validate the T2–FLAIR mismatch sign. Results: Among TCGA/TCIA cases, interreader agreement was calculated for lesion homogeneity [κ = 0.234 (0.111–0.358)], T2–FLAIR mismatch sign [κ = 0.728 (0.538–0.918)], lesion margins [κ = 0.292 (0.135–0.449)], and peritumoral edema [κ = 0.173 (0.096–0.250)]. All 15 cases that were positive for the T2–FLAIR mismatch sign were IDH-mutant, 1p/19q non-codeleted tumors (P < 0.0001; PPV = 100%, NPV = 54%). Analysis of the validation cohort demonstrated substantial interreader agreement for the T2–FLAIR mismatch sign [κ = 0.747 (0.536–0.958)]; all 10 cases positive for the T2–FLAIR mismatch sign were IDH-mutant, 1p/19q non-codeleted tumors (P < 0.00001; PPV = 100%, NPV = 76%). Conclusions: Among lower-grade gliomas, T2–FLAIR mismatch sign represents a highly specific imaging biomarker for the IDH-mutant, 1p/19q non-codeleted molecular subtype. Clin Cancer Res; 23(20); 6078–85. ©2017 AACR.

21 May 2020 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
AFA.M. Franceschi
A.M. Franceschi
OAO. Ahmed
O. Ahmed
LGLuca Giliberto
Luca Giliberto
MCM. Castillo
M. Castillo
SUMMARY: We describe 2 hospitalized patients with confirmed coronavirus 19 (COVID-19) infection in whom brain imaging showed hemorrhagic posterior reversible encephalopathy syndrome, and we discuss the possible reasons for these findings and their relationship to the infection.

1 October 2017 in Radiology
Verified
Journal Article
Closed access
NMNityanand Miskin
Nityanand Miskin
HPHersh Patel
Hersh Patel
AFAna M. Franceschi
Ana M. Franceschi
BABenjamin Ades-Aron
Benjamin Ades-Aron
ALAlexander Le
Alexander Le
FIFor The Alzheimer’s Disease Neuroimaging Initiative
For The Alzheimer’s Disease Neuroimaging Initiative
Our proposed prediction model on the basis of callosal angle and Evans index may serve as a screening tool to help the radiologist identify patients with possible normal-pressure hydrocephalus and ... Purpose To assess the diagnostic performance of the callosal angle (CA) and Evans index (EI) measures and to determine their role versus automated volumetric methods in clinical radiology. Material...

23 August 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
PCPetrice M. Cogswell
Petrice M. Cogswell
TATrevor J. Andrews
Trevor J. Andrews
JBJerome A. Barakos
Jerome A. Barakos
FBFrederik Barkhof
Frederik Barkhof
SBSuzie Bash
Suzie Bash
DGDementia Study Group
Dementia Study Group
With the full FDA approval and centers for Medicare & Medicaid services (CMS) coverage of lecanemab and donanemab, a growing number of practices are offering anti-amyloid immunotherapy to appropriate patients with cognitive impairment (MCI) or mild dementia due to amyloid-positive Alzheimer’s disease (AD). The goal of this paper is to provide updated practical considerations for radiologists, including implementation of MR imaging protocols, workflows and reporting and communication practices relevant to anti-amyloid immunotherapy and monitoring for amyloid-related imaging abnormalities (ARIA). Based on consensus discussion within an expanded ASNR Alzheimer’s, ARIA, and Dementia study group, we will: (1) summarize the FDA guidelines for evaluation of radiographic ARIA; (2) review the three key MRI sequences for ARIA monitoring and standardized imaging protocols based on ASNR-industry collaborations; (3) provide imaging recommendations for three key patient scenarios; (4) highlight the role of the radiologist in the care team for this population; (5) discuss implementation of MRI protocols to detect ARIA in diverse practice settings; and (6) present results of the 2023 ASNR international neuroradiologist practice survey on dementia and ARIA imaging. ABBREVIATIONS: AD = Alzheimer’s disease; ARIA = amyloid-related imaging abnormalities; APOE = apolipoprotein-E; CMS = centers for Medicare & Medicaid services; MCI = mild cognitive impairment.

21 February 2022 in Current Opinion in Neurology
Verified
Journal Article
Closed access
GPGabriel Cassinelli Petersen
Gabriel Cassinelli Petersen
MRMichelle Roytman
Michelle Roytman
GCGloria C. Chiang
Gloria C. Chiang
YLYi Li
Yi Li
MGMarc L. Gordon
Marc L. Gordon
AFAna M. Franceschi
Ana M. Franceschi
Purpose of review: This article reviews tau PET imaging with an emphasis on first-generation and second-generation tau radiotracers and their application in neurodegenerative disorders, including Alzheimer's disease and non-Alzheimer's disease tauopathies. Recent findings: Tau is a critical protein, abundant in neurons within the central nervous system, which plays an important role in maintaining microtubules by binding to tubulin in axons. In its abnormal hyperphosphorylated form, accumulation of tau has been linked to a variety of neurodegenerative disorders, collectively referred to as tauopathies, which include Alzheimer's disease and non-Alzheimer's disease tauopathies [e.g., corticobasal degeneration (CBD), argyrophilic grain disease, progressive supranuclear palsy (PSP), and Pick's disease]. A number of first-generation and second-generation tau PET radiotracers have been developed, including the first FDA-approved agent [18F]-flortaucipir, which allow for in-vivo molecular imaging of underlying histopathology antemortem, ultimately guiding disease staging and development of disease-modifying therapeutics. Summary: Tau PET is an emerging imaging modality in the diagnosis and staging of tauopathies.

1 January 2016 in Journal of Computer Assisted Tomography
Verified
Journal Article
Closed access
AFAna Marija Franceschi
Ana Marija Franceschi
SMStergios J. Moschos
Stergios J. Moschos
CACarey K. Anders
Carey K. Anders
SGSamuel Bsc Glaubiger
Samuel Bsc Glaubiger
FCFrances A. Collichio
Frances A. Collichio
YLYueh Z Lee
Yueh Z Lee
Purpose Susceptibility-weighted imaging (SWI) has significantly increased our sensitivity in detecting hemorrhagic brain lesions. We sought to explore the prevalence of intratumoral hemorrhage as detected by SWI in brain metastases from melanoma and breast cancer. Methods Lesions with a size of 0.1 cm3 were categorized as micrometastases, whereas larger lesions were categorized as macrometastases. Susceptibility-weighted imaging findings on locations corresponding to enhancing lesions were categorized as either positive or negative based on presence/absence of signal dropout. The percentage of SWI positivity was then estimated as a function of lesion size. Two-tailed Fisher exact test was performed to examine differences in the contingency tables. Results Magnetic resonance imaging studies from 73 patients with 1173 brain metastases, which enhanced on postcontrast T1-weighted imaging (T1WI) were selected for analysis. Of these lesions, 952 had SWI data available, and 342 of 952 were micrometastases. Only 10 of the 342 micrometastases and 410 (67.2%) of the 610 macrometastases were SWI positive (P < 0.0001). When examined by tumor type, 76.9% (melanoma) versus 55.6% (breast cancer) were SWI positive (P < 0.0001), regardless of tumor size. All melanoma lesions (8/8) and only 1 of 15 breast cancer lesions larger than 1.5 cm3 were SWI positive. Conclusion With the use of combined SWI and contrast-enhanced high-resolution T1 imaging, we found that presence of intratumoral brain hemorrhage is uncommon in micrometastases but common in metastases greater than 0.1 cm3 from breast cancer or melanoma. Large metastases commonly harbored hemorrhage, and this occurred more frequently in patients with melanoma than with breast cancer.